Robin Grant Research Group

Research in a Nutshell

Management of symptoms of primary brain tumour and the side effects of treatment are of major importance to patients, with the most common complaints in the clinic being fatigue, cognitive problems (especially poor memory), mood related issues, fear of the tumour coming back and seizures.

Clinical Trials in Prevention and treating Tumour Associated Epilepsy.

Drugs used to treat these symptoms may interfere positively (help) or negatively (hinder) with the ability of chemotherapies and other treatments to be effective at treating the tumour. These important drug-drug interactions are the focus of Dr Grant’s clinical research along with evidence-based evaluation of therapies.

• Consultant Neurologist in the Department of Clinical Neurosciences, Western General Hospital, Edinburgh
• Trained in Neuro-Oncology in University of Michigan Medical Center and Memorial Sloan Kettering Cancer Center in 1999-2000
• Established the Edinburgh Centre for Neuro-Oncology in 2003
• Clinical research interest lie in symptoms research (tumour associated epilepsy, cognition, mood and fatigue) and quality of life in neuro-oncology and evidence based medicine
• Advised on the evidence tumour associated epilepsy section of the EFNS:EANO low grade glioma guidelines and Palliative Care Guidelines
• President of the European Association for Neuro-Oncology (2008-10)
• Established and coordinating editor of Cochrane Neuro-Oncology Group
• Led the James Lind Alliance Neuro-Oncology Group http://www.jla.nihr.ac.uk/priority-setting-partnerships/neuro-oncology/
• Lead of NCRI brain Supportive & Palliative Care Subgroup. http://neuro-oncology.org.uk/index.php
• Advised on many Neuro-Oncological clinical, research and regulatory committees in UK and Europe
• European Lead VIBES Study.